IJJ Corp.
SILVER SPRING, MD / ACCESSWIRE / August 2, 2021 / IJJ Corporation (OTC PINK:IJJP):
IJJP News Headliners:
STOP SIGN REMOVAL: Pink Current Information status is waiting on the next OTCIQ's review.
Update: Responded to 3 different updates request by OTCIQ after the initial review of Financial and Disclosure information.
We received the following requests, which were updates and restating financial statements:
- A resubmission was required to post separate Annual Disclosure statement for 2019 and 2020,
- Additionally, due to the lapse of time between the initial submission also the 2nd Quarter Reports ending April 30, 2021, automatically was added to execute the OTCmarkets Agreement, which was activated.
- Next, we quoted on the Disclosure Statements one of the 5% shareholders name as entered on the register, which was a business name, when a point of contact was required.
- The Transfer Agent aided in providing the corrections, now reflected on the Shareholder list, and submitted as required.
- Lastly, correcting misquotes of Outstanding Shares between the Disclosure and Financials from 2019, revisions posted July 23, 2021.
eCETP SCOPE OF WORK: Encompasses the development of an eCETP dashboard user experience web and cloud-based application providing Key Performance Indicators (KPI) and customizable analytical stats with a downloadable client interface, with offsite storage and retrievals.
eCETP will offer donor packages for processing as Account Receipts Ticket for donation campaigns. Providing campaign analytical data on the expected values obtained within various levels by analyzing the variances that occurred during the campaign.
Phase 1 Update: On July 26, 2021, MonTech Corporation completed the delivery of the White Paper, the UI (User Interface) and UX (User experience) and the Non-functional prototype services for eCETP.
Special Update: A retraction on releasing the White Paper: After Montech team's technical review and during the rewrite several modifications required for the Web/Application design to be added to the White Paper to reflect the specification changes.
The release date is on or before the second week of August 2021, once item 2 below is completed.
Website https://Montech.io
Phase 2: eCETP Web/Application design stages:
Projected delivery: October 2021.
Item | PHASE 2 TASKS | DESCRIPTION |
1. | Custom Front-end Application Interfaces: | eCEPT INTERFACE (WebApplication)(Mobile Interfaces) ADMIN DASHBOARD INTERFACE (WebApplication). |
2. | Custom NodeJS Server: | Developing Node.js open-source back-end framework built in JavaScript to create web application performance, efficiencies, data-driven, and scalable |
3. | Optimization/Support Modules: | Modules to enhance the user experience and application performance encompassing redesign modifications. |
4. | eCETP Environment Solidity Smart-Contract Build: | As defined per eCETP White Paper specifications. |
5. | Project Management plan after approval of the above tasks: | The deployment of a Project management to schedule and track deliverables, necessary to complete the eCETP build out using multiple 3rd party providers. |
The next business development areas:
- The implementation of a Mandatory Training Program:
- The search for a Donation Campaign Specialist and a virtual developer for the Mandatory Training Course, as started.
- Training is designed to qualify trainees as certified Alliance Partners.
- The Mandatory Training Course provides a free training product package to the prospective Alliance Partner to create and deploy the resources to conduct a live campaign that generates working capital, "Without A Commitment To Join".
- The Mandatory Training allows them to establish a repeatable Donation Campaign that they can expand upon.
- The Steering Committee structure from onboarding officers is the last effort to drive the technical approach, Market Maker support, and business relationships after launching eCETP.
The above information is for IJJP Shareholders, and Market Makers. We will continue to post on twitter, LinkedIn posts, provide News Releases on material events, when a task is completed, and/or on any discoveries, as they occur.
The plan to redesign IJJ Corporation website will be announced on social media in late August 2021.
About IJJ Corp: IJJ Corp is an ambitious innovative company offering Business Processing as a Service (BPaaS) and a Blockchain Cryptographic exchanger within a private network designed to give access to investors, budget funding services, and networking business services.
The Company's aim is to continue to develop and integrate services and products to bring the most comprehensive, innovative, turnkey solutions and management services to its clients.
The Company will issue additional Press Releases on the status of the items referred to above within the next few weeks.
Follow IJJCorp on Twitter and LinkedIn at the following social media addresses:
https://twitter.com/IJJCorp and https://www.linkedin.com/company/ijj-corporation.
Safe Harbor Statement: The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.
CONTACT: info@ijjc.com
SOURCE: IJJ Corp.
View source version on accesswire.com:
https://www.accesswire.com/657912/IJJ-Corporation-OTCIJJP-OTCIQ-Update-and-News-on-eCommerce-Exchange-Trading-Platform-eCETP-Development-Progress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
